Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 2016 60 0?
Displaying drugs 1101 - 1125 of 2016 in total
NNC-55-0396 is a T-type Ca(2+) channel inhibitor.
Investigational
Investigational
Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also...
Investigational
VLX-1570 is under investigation in clinical trial NCT02372240 (A Study of VLX1570 and Dexamethasone in Myeloma Patients).
Investigational
Investigational
Investigational
AVR-RD-02 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary...
Investigational
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Investigational
Experimental
alpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).
Investigational
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
Experimental
Withdrawn
Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
Investigational
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.[A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.[A234215,...
Investigational
Investigational
Mitoglitazone has been used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.
Investigational
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60
Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or...
Investigational
Matched Description: … most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60
Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.
Investigational
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular …
Investigational
MORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Investigational
Investigational
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
Displaying drugs 1101 - 1125 of 2016 in total